<DOC>
	<DOCNO>NCT00121173</DOCNO>
	<brief_summary>RATIONALE : Vaccines make protein DNA may help body build effective immune response kill abnormal cell cervix . The use vaccine therapy may prevent cervical cancer . PURPOSE : This phase I/II trial study side effect best dose vaccine therapy see well work prevent cervical cancer patient cervical intraepithelial neoplasia human papillomavirus .</brief_summary>
	<brief_title>Vaccine Therapy Preventing Cervical Cancer Patients With Cervical Intraepithelial Neoplasia</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility toxicity pNGVL4a-Sig/E7 ( detox ) /HSP70 DNA vaccine prevent cervical cancer patient human papillomavirus ( HPV ) -16-positive grade 2 3 cervical intraepithelial neoplasia . - Determine effect vaccine histology cervical tissue specimens patient . Secondary - Determine change lesion size HPV viral load patient treat vaccine . - Determine cellular , humoral , local tissue immune response patient treat vaccine . - Correlate measure immune response clinical response patient treat vaccine . - Correlate measure immune response patient treat vaccine observed preclinical model . OUTLINE : This phase I , dose-escalation study follow phase II study . - Phase I : Patients receive pNGVL4a-Sig/E7 ( detox ) /HSP70 DNA vaccine subcutaneously week 0 , 4 , 8 absence disease progression unacceptable toxicity . Patients undergo colposcopy week 8 , 15 19 therapeutic loop electrosurgical excision procedure ( LEEP ) week 15 . Cohorts patient receive escalate dos vaccine safe dose determine . - Phase II : Patients receive vaccine phase I safest dose determined phase I . Patients also undergo colposcopy LEEP phase I . After completion study treatment , patient follow annually 15 year . PROJECTED ACCRUAL : Approximately 150 patient ( approximately 12 treated phase I 25 treat phase II ) accrue study .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Detox adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm cervical intraepithelial neoplasia Grade 2 3 disease Human papillomavirus16positive disease PATIENT CHARACTERISTICS : Age Over 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Other Not pregnant Negative pregnancy test Fertile patient must use effective contraception 3 month completion study treatment Must immunocompetent PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior hysterectomy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>cervical cancer</keyword>
	<keyword>cervical intraepithelial neoplasia grade 2</keyword>
	<keyword>cervical intraepithelial neoplasia grade 3</keyword>
</DOC>